Search results
Jun 8, 2023 · With two COVID-19 pills available, you may wonder if one is more effective. We look at the efficacy, side effects, and costs of Paxlovid vs. molnupiravir (Lagevrio) when used to treat COVID-19.
Key Points. Paxlovid (nirmatrelvir and ritonavir) and Lagevrio (molnupiravir) are two oral treatment options for mild-to-moderate coronavirus disease 2019 (COVID-19) in people who are at high risk for severe COVID-19 disease. Both Paxlovid and Lagevrio are taken by mouth twice a day for 5 days, and should be started within 5 days of COVID-19 ...
Compare Lagevrio vs Paxlovid head-to-head with other drugs for uses, ratings, cost, side effects and interactions.
Sep 22, 2022 · The primary outcome was to assess the risk of any-cause hospitalization within 48 hours and 30 days after initiation of COVID-19 antiviral therapies or diagnosis of COVID-19. Secondary outcomes included the risk for intensive care unit (ICU) care, intubation/respiratory support, and mortality.
Sep 28, 2023 · New Cleveland Clinic-led research shows commonly used COVID-19 anti-viral drugs Paxlovid (nirmatrelvir) and Lagevrio (molnupiravir) reduce risk of hospitalization and death in high-risk patients with mild disease, even with Omicron subvariants.
Dec 14, 2023 · These results show that molnupiravir works effectively and the study also demonstrated a positive benefit-risk balance for the treatment of mild to moderate COVID-19 in adults at high risk for disease progression.
If Paxlovid and Veklury (remdesivir) are not available, feasible or clinically appropriate, consider Lagevrio.1 COVID-19 Convalescent plasma is an additional authorized therapy for specific immunocompromised patients. This resource will be regularly reviewed and updated.
